170 related articles for article (PubMed ID: 17270214)
1. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma.
Higashi Y; Suzuki S; Sakaguchi T; Nakamura T; Baba S; Reinecker HC; Nakamura S; Konno H
J Surg Res; 2007 May; 139(1):68-76. PubMed ID: 17270214
[TBL] [Abstract][Full Text] [Related]
2. Expression of tight junction protein claudin-5 in tumor vessels and sinusoidal endothelium in patients with hepatocellular carcinoma.
Sakaguchi T; Suzuki S; Higashi H; Inaba K; Nakamura S; Baba S; Kato T; Konno H
J Surg Res; 2008 Jun; 147(1):123-31. PubMed ID: 17981296
[TBL] [Abstract][Full Text] [Related]
3. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
5. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of E-cadherin, CD34 in the patients with hepatocellular carcinoma].
Wu LQ; Lu Y; Lu HJ; Zhang B; Yang JY; Ma X
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):774-7. PubMed ID: 16836930
[TBL] [Abstract][Full Text] [Related]
7. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
9. Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma.
Cho SB; Lee KH; Lee JH; Park SY; Lee WS; Park CH; Kim HS; Choi SK; Rew JS
Pathol Int; 2008 Oct; 58(10):635-42. PubMed ID: 18801083
[TBL] [Abstract][Full Text] [Related]
10. N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.
Akiba J; Ogasawara S; Kawahara A; Nishida N; Sanada S; Moriya F; Kuwano M; Nakashima O; Yano H
Oncol Rep; 2008 Dec; 20(6):1329-35. PubMed ID: 19020710
[TBL] [Abstract][Full Text] [Related]
11. Significance of the serum level of soluble E-cadherin in patients with HCC.
Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
[TBL] [Abstract][Full Text] [Related]
12. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
[TBL] [Abstract][Full Text] [Related]
13. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
15. Fascin expression in progression and prognosis of hepatocellular carcinoma.
Iguchi T; Aishima S; Umeda K; Sanefuji K; Fujita N; Sugimachi K; Gion T; Taketomi A; Maehara Y; Tsuneyoshi M
J Surg Oncol; 2009 Dec; 100(7):575-9. PubMed ID: 19697358
[TBL] [Abstract][Full Text] [Related]
16. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition.
Park MY; Kim KR; Park HS; Park BH; Choi HN; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Int J Oncol; 2007 Dec; 31(6):1309-15. PubMed ID: 17982656
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.
Koga H; Sakisaka S; Ohishi M; Kawaguchi T; Taniguchi E; Sasatomi K; Harada M; Kusaba T; Tanaka M; Kimura R; Nakashima Y; Nakashima O; Kojiro M; Kurohiji T; Sata M
Hepatology; 1999 Mar; 29(3):688-96. PubMed ID: 10051469
[TBL] [Abstract][Full Text] [Related]
18. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
[TBL] [Abstract][Full Text] [Related]
19. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
20. [Expression of FADD in primary hepatocellular carcinoma and its relationship with hepatic apoptosis].
Sun B; Wang B; Zhao X
Zhonghua Gan Zang Bing Za Zhi; 2000 Feb; 8(1):37-9. PubMed ID: 10712784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
